Published in Cancer Invest on January 01, 2001
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10
Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol (2011) 1.04
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci U S A (2003) 1.02
PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest (2009) 0.92
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 4.50
Effects of corticosteroid therapy on human monocyte function. N Engl J Med (1975) 1.96
Effects of corticosteroids on human monocyte function. J Clin Invest (1974) 1.81
Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply. Arch Pathol Lab Med (2013) 1.78
Adriamycin cardiotoxicity in man. Ann Intern Med (1974) 1.66
Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans. Mod Pathol (1993) 1.48
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer (2009) 1.46
Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer (1993) 1.44
Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol (1990) 1.42
Variation in reference cells for DNA analysis of paraffin-embedded tissue. Am J Clin Pathol (1992) 1.40
The mechanism of retrovirus suppression of human T cell proliferation in vitro. J Immunol (1983) 1.39
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer (1995) 1.34
The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Hum Pathol (1996) 1.26
Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet (2005) 1.20
Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection. J Urol (1998) 1.18
Differentiation-associated alteration in human monocyte-macrophage accessory cell function. J Immunol (1983) 1.08
Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate (2001) 1.08
Human monocyte and macrophage modulation of lymphocyte proliferation. Cell Immunol (1979) 1.07
Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology (2007) 1.06
Cell-cell interaction in erythropoiesis. Role of human monocytes. J Clin Invest (1978) 1.06
Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med (2000) 1.05
Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol (2009) 1.03
The dedifferentiation of metastatic prostate carcinoma. Br J Cancer (1989) 1.03
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer (1994) 0.97
The effect of gamma interferon on IL-1 secretion of in vitro differentiated human macrophages. J Leukoc Biol (1985) 0.97
Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch Pathol Lab Med (2003) 0.96
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol (1999) 0.94
Human monocyte-induced tumor cell cytotoxicity. Blood (1978) 0.93
Characterization and comparison of human monocyte- and macrophage-induced tumor cell cytotoxicity. J Lab Clin Med (1979) 0.93
Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer (1991) 0.92
Enhancement of Fc receptor function during human monocyte differentiation in vitro. J Reticuloendothel Soc (1981) 0.91
Corticosteroid alteration of human monocyte to macrophage differentiation. J Immunol (1982) 0.91
Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst (1991) 0.89
Induction of peritoneal endometriosis in nude mice with use of human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in humans. Fertil Steril (2008) 0.87
Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol (1998) 0.87
Lysozyme stimulates lymphocyte proliferation in monocyte-depleted mixed lymphocyte cultures. J Lab Clin Med (1982) 0.87
Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer (1994) 0.86
Significance of nondiagnostic fine-needle aspiration of the thyroid. South Med J (1997) 0.85
Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clin Lung Cancer (2001) 0.84
Interleukin 1 secretion by human monocytes and macrophages. J Leukoc Biol (1984) 0.83
Interleukin 1 secretion is not required for human macrophage support of T-cell proliferation. Cell Immunol (1984) 0.83
Mesenchymal chondrosarcoma. A cytogenetic, immunohistochemical and ultrastructural study. Cancer Genet Cytogenet (1995) 0.82
Combined Fontana-Masson-mucin staining of Cryptococcus neoformans. Arch Pathol Lab Med (1991) 0.82
Unusual case of stridor and wheeze in an infant: tracheal bronchogenic cyst. Pediatr Pulmonol (2002) 0.82
Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma. J Biol Response Mod (1986) 0.82
Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother (1991) (1991) 0.82
Atypical hyperplasia in prostates of 20 to 40 year old men. J Clin Pathol (1989) 0.80
Best cases from the AFIP: primary hyperparathyroidism due to parathyroid adenoma. Radiographics (2005) 0.80
Benign breast disease. Obstet Gynecol Clin North Am (2008) 0.80
Lysozyme enhances monocyte-mediated tumoricidal activity: a potential amplifying mechanism of tumor killing. Blood (1981) 0.79
Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer. Cancer Treat Rep (1987) 0.79
Protein C deficiency. South Med J (1987) 0.79
Microfilament and microtubule function in human monocytes. J Lab Clin Med (1977) 0.79
Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma. J Clin Oncol (1990) 0.78
T-cell subset modulation of blood erythroid burst-forming unit proliferation. J Lab Clin Med (1983) 0.78
Tumor necrosis factor infusions in humans prime neutrophils for hypochlorous acid production. Am J Physiol (1990) 0.78
Modulation of adhesion molecules on human large granular lymphocytes by interleukin-2 in vivo and in vitro. Cell Immunol (1992) 0.78
Addition (1)(q32) as the sole clonal chromosomal abnormality in a case of cardiac myxoma. Cancer Genet Cytogenet (1997) 0.78
Induction of nonspecific, proliferative dependent suppressor T lymphocytes in human mixed lymphocyte cultures. Cell Immunol (1980) 0.78
Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates. Prostate (1996) 0.78
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis. Ann Pharmacother (1998) 0.77
Incidence, racial differences, and prognostic significance of prostate carcinomas diagnosed with obstructive symptoms. Cancer (1994) 0.77
Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1. Exp Hematol (1992) 0.77
Human peripheral blood erythroid burst forming unit (BFU(E)): evidence against T-lymphocyte requirement for proliferation in vitro. Exp Hematol (1980) 0.77
Angiotropic lymphoma manifested by fever and painful swollen legs. South Med J (1993) 0.77
Effects of YM 435 and A 77636 on dopamine D-1 receptors in bovine retina in vitro. Gen Pharmacol (1995) 0.77
Central nervous system toxicity of biological response modifiers. Ann N Y Acad Sci (1990) 0.77
Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH. Br J Cancer (1994) 0.77
T-lymphocytes as a prognostic indicator in head and neck cancer. Arch Otolaryngol Head Neck Surg (1986) 0.76
Frozen section diagnosis of metastatic prostate adenocarcinoma in pelvic lymphadenectomy compared with nomogram prediction of metastasis. Urology (2002) 0.76
Human monocyte to macrophage differentiation in vitro: characterization and mechanisms of the increased antibody-dependent cytotoxicity associated with differentiation. J Leukoc Biol (1984) 0.76
Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep (1987) 0.76
Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol (1991) 0.76
Biological and clinical effects of interferon-beta ser at two doses. J Interferon Res (1990) 0.76
TTF-1 and napsin A do not differentiate metastatic lung adenocarcinomas from primary esophageal adenocarcinomas: proposal of a novel staining panel. Arch Pathol Lab Med (2013) 0.76
Spleen cell population changes and hemolytic anemia in F344 rats with large granular lymphocyte leukemia. Vet Pathol (1990) 0.75
Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects. Cancer Res (1987) 0.75
Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin Oncol (1995) 0.75
Impact of metastases on nodal immunoreactivity in head and neck cancer. Laryngoscope (1986) 0.75
Pituitary component of the aromatic hydrocarbon-mediated expression of CYP2B and CYP2C11. Xenobiotica (1998) 0.75
Inhibition of in vitro plaque formation by large granular lymphocyte leukemia cells from F344 rats. J Clin Lab Immunol (1990) 0.75
Ultrasound detection of prostate cancer in postmortem specimens with histological correlation. J Urol (1992) 0.75
Primary lymphoma of the liver mimicking metastatic liver disease. South Med J (1995) 0.75
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group. Cancer (1996) 0.75
Merkel cell carcinoma with pagetoid spread. Ultrastruct Pathol (1992) 0.75
Weight change and peptide hormone responses in patients receiving interferon. Nutr Cancer (1987) 0.75
A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer. J Immunother (1991) (1992) 0.75
Human monocytes inhibit lymphokine-activated killer cell expansion in vitro. Mol Biother (1991) 0.75
Aci-reductones enhance interleukin-2-induced lymphocyte cytotoxicity. Int J Immunopharmacol (1993) 0.75
Lack of significant changes in nutrition-related parameters with tumor necrosis factor treatment of cancer. Nutr Cancer (1993) 0.75
Cytogenetic abnormalities in renal oncocytic neoplasms. Genes Chromosomes Cancer (1992) 0.75
Immunomodulation of nodal lymphocytes in head and neck cancer. Arch Otolaryngol (1985) 0.75
Aneuploidy in benign seminal vesicle epithelium: an example of the paradox of ploidy studies. Mod Pathol (1991) 0.75
Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects. J Biol Response Mod (1987) 0.75
Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2. Cancer Res (1986) 0.75